ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
ed in different studies classified as: duodenal carcinoid; duodenal gastroenteropancreatic (GEP) tumor; duodenal pancreatic neuroendocrine tumor (p-NET); duodenal gastrinoma; duodenal somatostatinoma; gangliocytic paraganglioma; ampullary carcinoid or somatostatinoma; argentaffin carcinoid-producing serotonin of the duodenum; psammomatous somatostatinoma; duodenal NE carcinoma, poorly differentiated and small-cell NE carcinoma of the duodenum [6] . The clinical and management aspect of duodenal gastrinomas are included in the ‘Endocrine Tumors of the Pancreas – Gastrinoma’ section and duodenal gastrinomas will only be considered in this section in comparison with the other d-NENs. Introduction Gastric neuroendocrine neoplasms (g-NENs) [1] are increasingly recognized due to expanding indications of upper gastrointestinal (UGI) endoscopy. Often silent and benign, g-NENs may, however, be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Duodenal neuroendocrine tumors (d-NENs) [2] may or may not be associated with a functional clinical syndrome. The term d-NEN includes all duodenal tumors with neuroendocrine (NE) features as determined by histological/immunohistochemical methods including positivity for NE cytosolic markers (neuron-specific enolase (NSE), PGP 9.5) or secretory vesicle proteins (chromogranin A (CgA), synaptophysin) and also frequently the presence of specific gastrointestinal (GI) hormones [3–8] . The term d-NEN in this paper refers to tumors includ- Published online: February 15, 2012 Gianfranco Delle Fave Digestive and Liver Disease Unit ‘Sapienza’ University of Rome, Sant’Andrea Hospital Via Di Grottarossa 1035–1039, IT–00189 Rome (Italy) Tel. +39 06 3377 5691, E-Mail gianfranco.dellefave @ uniroma1.it © 2012 S. Karger AG, Basel 0028–3835/12/0952–0074$38.00/0 Accessible online at: www.karger.com/nen 1
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These tumors develop as a consequence of the parietal cell loss, which leads to reduced gastric acid secretion and downstream persistent hypergastrinemia, enterochromaffin-like cell (ECL) hyperplasia, and, in a small percentage, ECL dysplasia and gastric NETs.27”
From AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021) · cites this paper as [27]
Citations
Cites
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & HARMON, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2157::aid-cncr2820730821>3.0.co;2-1 · Cited by 2,135
(2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Paraganglioma of the filum terminale internum
Kamalian, N., Abbassioun, K., Amirjamshidi, A., & Shams-Shahrabadi, M. (1987) · Journal of Neurology · doi:10.1007/bf00314201 · Cited by 1,594
Report of a case and review of the literature
Kamalian, N., Abbassioun, K., Amirjamshidi, A., et al. (1987) · Cited by 1,576
THE CLASSIFICATION OF CARCINOID TUMOURS
WILLIAMS, E. (1963) · The Lancet · doi:10.1016/s0140-6736(63)90951-6 · Cited by 885
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Self-citationThe Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification
KLÖPPEL, G., PERREN, A., & HEITZ, P. U. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.002 · Cited by 794
Histological Typing of Endocrine Tumours
Solcia, E., Klöppel, G., & Sobin, L. H. (2000) · Springer eBooks · doi:10.1007/978-3-642-59655-1 · Cited by 747
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Self-citation
Research works printed but not linked: 30
- Attanoos R, 1991, Semin Diagn Pathol, 8, 149
- Soga J, 1996, J Exp Clin Cancer Res, 15, 3
- Bordi C, 1999, Ital J Gastroenterol Hepatol, 31, S94
- Thomas RM, 1994, Cancer, 73, 2053, 10.1002/1097-0142(19940415)73:8<2053::aid-cncr2820730807>3.0.co;2-0 · DOI · Paper page
- Cattan D, 1991, Gastroenterol Clin Biol, 15, 30C
- Marignani M, 1999, Am J Gastroenterol, 94, 766
- Spinazzola AJ, 1963, Am Surg, 29, 405
- Walton GF, 1997, Am Surg, 63, 302
- Soga J, 1999, J Exp Clin Cancer Res, 18, 13
- Taccagni GL, 1986, Am J Gastroenterol, 81, 33
- Burke AP, 1990, Arch Pathol Lab Med, 114, 700
- Capella C, 1990, Hepatogastroenterology, 37, 247
- Heymann MF, 2004, Hepatogastroenterology, 51, 1367
- Soga J, 2003, J Exp Clin Cancer Res, 22, 349
- Thom AK, 1991, Surgery, 110, 1086
- Zogakis TG, 2003, Ann Surg, 238, 42
- Gibril F, 2004, Medicine, 83, 43, 10.1097/01.md.0000112297.72510.32 · DOI · Paper page
- Cohen T, 1981, Am J Gastroenterol, 75, 197
- Amano S, 1978, Acta Pathol Jpn, 28, 721
- Orbuch M, 1995, Karger, 23, 268
- Yoshikane H, 1995, Am J Gastroenterol, 90, 642
- Meijer WG, 2003, J Nucl Med, 44, 184
- Lebtahi R, 1999, J Nucl Med, 40, 1602
- Hubalewska-Dydejczyk A, 2005, Nucl Med Rev Cent East Eur, 8, 155
- Taal BG, 2005, Minerva Gastroenterol Dietol, 51, 335
- Sato T, 2005, Hepatogastroenterology, 52, 678
- Horsley GW, 1957, Surg Gynecol Obstet, 105, 417
- Thompson GB, 1985, Surgery, 98, 1054
- Yoshikane H, 1993, Gastrointest Endosc, 39, 375, 10.1016/s0016-5107(93)70109-1 · DOI
- Kwekkeboom DJ, 2005, J Nucl Med, 46, 62S
Cited by
Items 101–200 of 328
Management and Prognosis of Localized Duodenal Neuroendocrine Neoplasms
Gay-Chevallier, S., de Mestier, L., Périnel, J., Forestier, J., Hervieu, V., Ruszniewski, P. B., Millot, I., Valette, P., Pioche, M., Lombard‐Bohas, C., et al. (2020) · Neuroendocrinology · doi:10.1159/000508102 · Cited by 15
Self-citationChildhood neuroendocrine tumors of the digestive system: A single center experience
Kartal, İ. (2022) · Medicine · doi:10.1097/md.0000000000028795 · Cited by 22
“GEP-NETs are very rare in the pediatric age group, as their highest prevalence is observed after the fifth decade of life.([4,5]) Among GEP-NETs, appendiceal neuroendocrine tumors (aNETs) are the most common, occurring in 78% to 79% of cases.”
Nießen, A., Bergmann, F., Hinz, U., Schimmack, S. J., Hackert, T., Büchler, M. W., & Strobel, O. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.01.030 · Cited by 15
Pimentel‐Nunes, P., Ortigão, R., Afonso, L. P., Bastos, R. P., Libânio, D., & Dinis-Ribeiro, M. J. (2022) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000521654 · Cited by 15
Surgical treatment of neuroendocrine tumors (including carcinoid)
Doherty, G. M. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835b7efa · Cited by 14
Weatherall, T. J., Denbo, J. W., Sharpe, J. P., Martin, M. G., O’Brien, T., Gupta, R. K., Groshart, K. D., Behrman, S. W., & Dickson, P. V. (2016) · World Journal of Surgery · doi:10.1007/s00268-016-3770-0 · Cited by 14
“For lesions 1–2 cm in size, endoscopic resection versus surgical resection is recommended [3].”
BackgroundMethodInfluentialLiu, H., Li, J., Liang, C., Chu, Y., Wang, Y., Lv, L., Liu, D., & Tan, Y. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-10706-0 · Cited by 13
Lv, Y., Huang, C., Xu, H., Han, X., Zhang, L., Mao, W., Ji, Y., Jin, D., Lou, W., & Xu, X. (2018) · Journal of Cancer · doi:10.7150/jca.22157 · Cited by 13
Ye, H., Yuan, Y., Chen, P., & Zheng, Q. (2022) · Surgical Endoscopy · doi:10.1007/s00464-022-09190-1 · Cited by 13
Kim, Y., Ahn, B., Choi, K. D., Kim, B. S., Yook, J. H., Lee, G. H., Hong, S., & Lee, J. H. (2023) · Gut and Liver · doi:10.5009/gnl220175 · Cited by 13
Ragheb, J. G., Mony, S., Klapman, J. B., Erim, T., Reagan, A., Butler, R. S., Dong, Y., Cruise, M. W., Centeno, B. A., Bejarano, P. A., et al. (2021) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.02.033 · Cited by 13
Endoskopische Therapie gastroduodenaler neuroendokriner Neoplasien
Maasberg, S., Jürgensen, C., Scheerer, F., Pschowski, R., Felder, S., Begum, N., Wiedenmann, B., Pascher, A., & Pape, U. (2016) · Der Chirurg · doi:10.1007/s00104-016-0157-6 · Cited by 13
Murugesan, S. V., Steele, I. A., Dimaline, R., Poston, G. J., Shrotri, M. S., Campbell, F., Varró, A., & Pritchard, D. M. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835cec52 · Cited by 13
Tumeurs neuroendocrines digestives
de Mestier, L., Deguelte, S., Brixi, H., Kianmanesh, R., & Cadiot, G. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.01.012 · Cited by 13
Panzuto, F., O’Toole, D., Klöppel, G., Knigge, U., Krejs, G. J., Tsoli, M., Volante, M., & Luong, T. V. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70060 · Cited by 12
Self-citationGupta, S., Kumar, P. R., Cahuin, R. C., Murino, A., Despott, E. J., Lemmers, A., Pioche, M., & Bourke, M. J. (2023) · Endoscopy International Open · doi:10.1055/a-2181-0320 · Cited by 12
Xu, X., Li, J., Han, X., Shi, C., Dayong, J., & Wenhui, L. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20132415 · Cited by 12
“Currently, the standard treatment for g-NEC patients is based on radical surgery and chemotherapy, similar to gastric adenocarcinoma.(6) In our study, 34 patients received adjuvant chemotherapy with regimen of oxaliplatin and 5-FU, referencing the regimens of gastric adenocarcinoma.”
Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature
Gaiani, F., de’Angelis, N., Minelli, R., Kayali, S., Carra, M. C., & de’Angelis, G. L. (2019) · Medicine · doi:10.1097/md.0000000000017154 · Cited by 13
“Given all the imaging results, the tumor was classified as NET G1.([4])”
InfluentialManagement of Other Gastric and Duodenal Neuroendocrine Tumors
Laird, A. M., & Libutti, S. K. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.11.009 · Cited by 12
Atrophic gastritis and pre-malignant gastric lesions
Lahner, E., Esposito, G., Galli, G., & Annibale, B. (2015) · Translational gastrointestinal cancer · Cited by 20
Tian, F., Cai, Y., Zhuang, L.-P., Ming-fang, C., Xiu, Z., Zhang, Y., Liu, H., Liu, Z., Liu, G., Zeng, C., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1683 · Cited by 12
Follow-up of patients with ECL cell-derived tumours
Sagatun, L., Fossmark, R., Jianu, C. S., Qvigstad, G., Nordrum, I. S., Mjønes, P., & Waldum, H. L. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2016.1169588 · Cited by 12
“guidelines, [17] with endoscopic follow-up of small and few”
BackgroundMethodInfluentialAtrophic Body Gastritis: Clinical Presentation, Diagnosis, and Outcome
Lahner, E., Carabotti, M., & Annibale, B. (2017) · EMJ Gastroenterology · doi:10.33590/emjgastroenterol/10314623 · Cited by 14
Neuroendokrine Neoplasien des distalen Jejunums und Ileums
Anlauf, M., Sipos, B., Boeck, I., Baldus, S. E., Heikaus, S., Krausch, M., Knoefel, W. T., Begum, N., Goretzki, P. E., Schott, M., et al. (2014) · Der Pathologe · doi:10.1007/s00292-013-1888-5 · Cited by 12
Nicolaou, A., Thomas, D., Alexandraki, K., Sougioultzis, S., Tsolakis, A. V., & Kaltsas, G. (2014) · Neuroendocrinology · doi:10.1159/000362879 · Cited by 13
Schulz, C., Schütte, K., & Malfertheiner, P. (2015) · Gastrointestinal Tumors · doi:10.1159/000435899 · Cited by 11
International Practice Patterns and Resource Utilization in the Treatment of Neuroendocrine Tumors
Casciano, R., Wang, X., Stern, L. S., Parikh, R. C., Chulikavit, M., Willet, J., Liu, Z., Strosberg, J., Cadiot, G., & Riechelmann, R. P. (2013) · Pancreas · doi:10.1097/mpa.0b013e31826707cc · Cited by 11
Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors
Kenney, L. M., & Hughes, M. S. (2025) · Cancers · doi:10.3390/cancers17030377 · Cited by 10
Khara, H. S., Shovlin, G., Johal, A. S., & Diehl, D. L. (2019) · Endoscopy International Open · doi:10.1055/a-0684-9563 · Cited by 10
“Current guidelines recommend that duodenal NETs less than 10mm in size, without infiltration of the muscularis propria, and no associated hormonal syndrome, have a low metastatic potential, and should be treated by endoscopic techniques [2].”
BackgroundInfluentialYan, S., Liu, T., Li, Y., Zhu, Y., Jiang, J., Jiang, L., & Zhao, H. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.114 · Cited by 10
“However, according to clinical classification from the ENETS guideline of gastroduodenal neoplasms (17), based on the fact of the absent of atrophic gastritis under endoscope and solitary lesion in all patients, we deemed they were all type III.”
MethodEndoscopy and Endoscopic Ultrasound in Assessing and Managing Neuroendocrine Neoplasms
O’Toole, D., & Palazzo, L. (2015) · Frontiers of hormone research · doi:10.1159/000382062 · Cited by 11
Enterochromaffin-like cell neuroendocrine tumor associated with parietal cell dysfunction
Ishioka, M., Hirasawa, T., Kawachi, H., Nakano, K., Kunieda, J., Yoshimizu, S., Horiuchi, Y., Ishiyama, A., Yoshio, T., Tsuchida, T., et al. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.06.029 · Cited by 10
Malczewska, A., Procner, A., Walter, A., Kuśnierz, K., Zajęcki, W., Aslanian, H. R., & Kos‐Kudła, B. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01348-2 · Cited by 11
Jiao, X., Wang, Z., Peng, X., Zhang, L., & Zhou, L. (2020) · Future Oncology · doi:10.2217/fon-2020-0150 · Cited by 10
Endoscopic mucosal resection with circumferential mucosal incision of duodenal carcinoid tumors
Otaki, Y. (2013) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v5.i4.197 · Cited by 10
Li, Y., Bi, X., Zhao, J., Huang, Z. K., Zhou, J., Li, Z., Zhang, Y., Li, M., Chen, X., Hu, X., et al. (2016) · Medicine · doi:10.1097/md.0000000000003567 · Cited by 10
“Approximately 14% to 25% of GNETs are classified as gastrin-independent; these GNETs are large (>2 cm, mean 5.1 cm), usually occur singly, and grow from the gastric body/ fundus in the context of normal (nonatrophic) surrounding mucosa.10 GNETs can be divided into 3 types according to ENETS Consensus Guidelines.9 Type…”
BackgroundInfluentialPapaefthymiou, A., Laskaratos, F., Koffas, A., Manolakis, A. C., Gkolfakis, P., Coda, S., Sodergren, M. H., Suzuki, N., & Toumpanakis, C. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00986-w · Cited by 10
Gao, P., Lin, S., Fu, P., Li, Q., Cai, M., Ma, L., Zhang, Y., Zhong, Y., Yao, L.-Q., Chen, W., et al. (2023) · Surgical Endoscopy · doi:10.1007/s00464-023-10013-0 · Cited by 9
Gopakumar, H., Jahagirdar, V., Koyi, J., Dahiya, D. S., Goyal, H., Sharma, N. R., & Perisetti, A. (2023) · Cancers · doi:10.3390/cancers15164175 · Cited by 9
Long-term outcomes of endoscopic resection for duodenal neuroendocrine tumors
Yi, K., Kim, G. H., Kim, S. J., Choi, C. W., Lee, M. W., Lee, B. E., & Song, G. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-45243-8 · Cited by 9
Si, Y., Huang, C., Yuan, J., Zhang, X., He, Q.-Q., Lin, Z., He, L. Y., & Liu, Z. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/5248256 · Cited by 9
Neoplasien des disseminierten neuroendokrinen Zellsystems des Gastrointestinaltrakts
Klöppel, G. (2015) · Der Pathologe · doi:10.1007/s00292-015-0015-1 · Cited by 9
Rydzewska, G. M., Cichocki, A. S., Ćwikła, J. B., Fołtyn, W., Hubalewska–Dydejczyk, A., Kamiński, G., Lewczuk, A., Nasierowska-Guttmejer, A. M., Nowakowska-Duława, E., Pilch-Kowalczyk, J., et al. (2014) · Endokrynologia Polska · doi:10.5603/ep.2013.0030 · Cited by 13
“Despite a low proliferation index, NENs G1 tend to recur, and the median recurrence-free survival is 24 months; however, the literature presents cases of transformation into NEC in 3% of patients [51].”
Self-citationArmstrong, E. A., Beal, E. W., Lopez‐Aguiar, A. G., Poultsides, G. A., Cannon, J. G. D., Rocha, F. G., Crown, A., Barrett, J. R., Ronnekleiv‐Kelly, S. M., Fields, R. C., et al. (2019) · The American Surgeon · doi:10.1177/000313481908501225 · Cited by 9
Imaging of neuroendocrine tumors
Sundin, A. (2012) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2012.692874 · Cited by 9
“When EUS-guided biopsy (fine needle aspiration cytology, FNAC or core biopsy and histology) confirms metastases CT or MRI and SRI is recommended further imaging.”
MethodInfluentialPetersenn, S., & Koch, C. A. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9442-7 · Cited by 9
Type-1 Grade 2 Multi-Focal Gastric Neuroendocrine Tumors Secondary to Chronic Autoimmune Gastritis
Yu, Z., Wang, A., Hu, C., Yu, T., & Chen, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.856125 · Cited by 9
“For treatment, simple endoscopic surveillance and endoscopic resection are recommended for type-1 G-NETs that are smaller than 20 mm by both National Comprehensive Cancer Network (NCCN) and European Neuroendocrine Tumor Society (ENETS) (26, 27).”
MethodLarge Cell Neuroendocrine Carcinoma of the Nasopharynx
Dumars, C., Thébaud, E., Joubert, M., Renaudin, K., Cariou-Patron, G., & Heymann, M. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000334 · Cited by 8
Kubo, K., Kimura, N., Mabe, K., Nishimura, Y., & Kato, M. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0842-18 · Cited by 8
“Gastric NETs are categorized into three types: type I, which is associated with autoimmune chronic atrophic gastritis; type II, which is associated with multiple endocrine neoplasia type 1 (MEN 1) and Zollinger-Ellison syndrome; and type III, which is shown to occur sporadically (11).”
BackgroundNeuroendocrine carcinoma of the stomach: clinical features and CT findings
Liang, P., Wang, Y., Ren, X.-C., & Gao, J. (2015) · Abdominal Radiology · doi:10.1007/s00261-015-0593-7 · Cited by 8
“The long-axis diameters and locations of the cases of G-NEC in our series were similar to those in previous reports [9, 15].”
ResultLahner, E., Esposito, G., Angeletti, S., Corleto, V. D., Pilozzi, E., Giulio, E. D., & Annibale, B. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000566 · Cited by 9
Schmidt, M. C., Uhrhan, K., Fischer, T. H., Schmitz, S. H., Markiefka, B., Drzezga, A. E., & Stippel, D. L. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000805 · Cited by 8
Pathology: Classification and Immunoprofile
Blank, A., Schmitt, A. M., & Perren, A. A. (2015) · Frontiers of hormone research · doi:10.1159/000382135 · Cited by 7
Genetics and Epigenetics of Pancreatic Neuroendocrine Tumors and Pulmonary Carcinoids
Dreijerink, K. M. A., Derks, J. L., Cataldo, I., Scarpa, A., Valk, G. D., & Speel, E. M. (2015) · Frontiers of hormone research · doi:10.1159/000382138 · Cited by 8
Minute Type I Gastric Carcinoid With Regional Lymph Node Metastasis
Lupinacci, R. M., Dias, A. R., de Mello, E. S., & Kondo, A. (2012) · International Journal of Surgical Pathology · doi:10.1177/1066896912457201 · Cited by 7
A unique tripartite collision tumor of the esophagus
Schizas, D., Michalinos, A., Alexandrou, P. T., Moris, D., Baliou, E., Tsilimigras, D. I., Throupis, T., & Liakakos, T. (2017) · Medicine · doi:10.1097/md.0000000000008784 · Cited by 7
Further Classification for Node-Positive Gastric Neuroendocrine Neoplasms
Pak, L. M., Yang, T., & Wang, J. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3845-3 · Cited by 7
Neuroendocrine Tumour as a Diagnostic and Prognostic Criterion for Autoimmune Gastritis
Mozgovoi, S. I., Livzan, M. A., Сергеевна, К. Т., & Геннадьевна, Ш. А. (2020) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2019-29-6-49-59 · Cited by 8
Zhou, Y., Wang, Q.-W., Zhang, Q., Chen, J.-N., Wang, X., Gao, Y., & Li, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.658392 · Cited by 7
“As indicated in ENETS guidelines, open surgery was recommended for type 1 gNENs with poor differentiation, metastasis, or muscularis propria invasion, and for all type 2 and type 3 g-NENs (6, 7).”
BackgroundMethodGastroenteropankreatische neuroendokrine Tumoren
Holzer, K. (2014) · Der Chirurg · doi:10.1007/s00104-013-2679-5 · Cited by 7
Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms
Zhang, Q., Wang, H., Xie, Y., Huang, S., Chen, K., Ye, B., Yang, Y., Sun, J., He, H., Liu, F., et al. (2021) · Endocrine Connections · doi:10.1530/ec-21-0017 · Cited by 6
Mirzaie, S., Park, J. Y., Mederos, M. A., & Girgis, M. D. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05800-y · Cited by 6
“6,7 14 In 2021, Tran et al. examined dNETs of different sizes in their cohort ( n = 104) and found that after adjusting for age, the method of resection had no significant association with survival.”
MethodSagatun, L., Mjønes, P., Jianu, C. S., Boyce, M. J., Waldum, H. L., & Fossmark, R. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000713 · Cited by 6
Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms
Tan, H. (2016) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2016.11.03 · Cited by 6
“Multiple specimens were collected from the tumor, and two or more mucosal specimens were obtained from gastric fundus, gastric body, and gastric antrum (15).”
BackgroundGuo, C., Ng, H., Liu, Y., Sun, C., Zhang, X., Zhao, D., & Wang, G. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000440 · Cited by 6
Mixed adenoneuroendocrine carcinoma of the esophagus: A case report and review of the literature
Mendoza‐Moreno, F., Díez-Gago, M., Mínguez-García, J., Iglesias, B. T., Hernández, G. Z., Fernández, S., Solana-Maoño, M., & Argüello-De-Andrés, J. (2018) · Nigerian Journal of Surgery · doi:10.4103/njs.njs_43_17 · Cited by 6
“[2,18] Other authors approve the choice of cisplatin combined with fluoropyrimidines in the presence of metastatic adenopathies.”
BackgroundImpériale, A., Avérous, G., Helali, M., Taïeb, D., Pessaux, P., Goichot, B., Addeo, P., & Bachellier, P. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01378-1 · Cited by 6
Hawa, F. N., Sako, Z., Nguyen, T., Catanzaro, A. T., Zolotarevsky, E., Bartley, A. N., & Gunaratnam, N. T. (2020) · Endoscopy International Open · doi:10.1055/a-1119-6698 · Cited by 6
“Regardless of the type (G-NETs or D-NETs), endoscopic resection is recommended as an initial treatment for tumors that are not yet at advanced stages [2, 3].”
BackgroundMethodAutoimmune gastritis: from symptom to diagnosis. Clinical observations
Livzan, M. A., Сергеевна, К. Т., Игоревич, М. С., Kostoglod, T. V. K., & Kostoglod, А. V. K. (2020) · Consilium Medicum · doi:10.26442/20751753.2020.8.200037 · Cited by 6
Wang, M., Shubang, C., Zhu, L., Xu, T., Zhang, J., Zhang, Y., Ping, J., & Wang, R. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07143-7 · Cited by 7
Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-Nets): A Review
Yi, C. C. X. (2013) · Journal of Gastrointestinal & Digestive System · doi:10.4172/2161-069x.1000154 · Cited by 6
“For gastric NETs, Type 1 can undergo endoscopic resection, and in cases with invasion beyond the sub-mucosa, positive resection margins after EMR, multiple tumors >1 cm or regional lymph node metastases, local resection or partial or total gastrostomy should be performed [85,86].”
BackgroundKubo, K., Kimura, N., Matsuda, S., Mabe, K., & Kato, M. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2679-19 · Cited by 5
“In addition, gastric NETs are categorized into three types: type I, NETs often seen in association with autoimmune chronic atrophic gastritis; type II, NETs associated with multiple endocrine neoplasia type 1 (MEN 1) and Zollinger-Ellison syndrome; and type III, aggressive NETs reported to occur only sporadically (3).”
BackgroundRiding a roller coaster: narrative typologies of patients with neuroendocrine tumors
Vatne, S., Miconi, A., Nuzzo, D. D., & Pierontognetti, P. (2015) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s90744 · Cited by 5
Multicentric Type 3 Gastric Neuroendocrine Tumors
Lee, S. H., Moon, D., Lee, H. S., Lee, C., Jeon, Y. D., Park, J. H., Kim, H., & Lee, S. K. (2015) · Clinical Endoscopy · doi:10.5946/ce.2015.48.5.431 · Cited by 5
“Thus, the therapeutic approach to type 3 gastric NETs should be managed surgically.(9) Only small (<10 mm), well differentiated (G1) type 3 gastric NETs limited to the submucosal layer have been treated efficaciously by endoscopic mucosectomy, in a retrospective analysis.”
BackgroundKurtulan, O., Turhan, N., Gedikog̈lu, G., Akyol, A., & Sökmensüer, C. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.8601 · Cited by 5
Feng, N., Chen, H., Lu, Y., Pan, Y., Yu, J., Wang, X.-B., Deng, X., & Yu, R. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05295-9 · Cited by 5
“Size, grade, depth of invasion, angioinvasion, and other factors could be related to long-term outcomes of dNENs (Delle Fave et al. 2012; Nießen et al. 2020).”
BackgroundManneh, R., Castellano, D., Caso, Ó., Loinaz, C., López, J. S. J., Estenoz, J., Calatayud, M., Sepúlveda-Sánchez, J. M., & García‐Carbonero, R. (2016) · Case Reports in Oncology · doi:10.1159/000445940 · Cited by 5
A New Robot-assisted Billroth-I Reconstruction: Details of the Technique and Early Results
Ceccarelli, G., Marano, L., Pisanelli, M. C., Andolfi, E., Biancafarina, A., Fabozzi, M., Caruso, S., & Patriti, A. (2018) · Surgical Laparoscopy Endoscopy & Percutaneous Techniques · doi:10.1097/sle.0000000000000505 · Cited by 5
Shenoy, V., James, J., Williams-Walker, A. B., Mohan, N., Hoang, K. N. L., Williams, J., Jaeckle, F., Evans, S. C., & Soilleux, E. J. (2025) · Diagnostics · doi:10.3390/diagnostics15121483 · Cited by 4
“Seronegative spondyloarthropathy 2 (0.88) 0.5–1.9% [ 56] Addison’s disease 2 (0.88) 0.01% [57] Transplanted ileum and colon 1 (0.44) 19 cases in 2018–19 [58] Duodenal neuroendocrine tumour 1 (0.44) 0.00017% [59] 1 NSAID—non-steroidal anti-inflammatory drug.”
InfluentialChirurgische Therapie gastroduodenaler neuroendokriner Neoplasien
Fendrich, V., & Bartsch, D. K. (2016) · Der Chirurg · doi:10.1007/s00104-015-0138-1 · Cited by 4
Tumores neuroendocrinos: experiencia de 6 años en un centro de tercer nivel
Grajeda, M. G. V., Ronquillo-Carreón, C. A., Mendoza, A. D. J. M., & Borunda, A. K. D. (2015) · Gaceta Mexicana de Oncología · doi:10.1016/j.gamo.2015.07.003 · Cited by 4
Epidemiology of Neuroendocrine Tumours: By Site of Tumour and by Geographical Area
Cavalcoli, F., Garrahy, A., Castellaneta, M., & Tamagno, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-59024-0_1 · Cited by 4
Mixed adenoneuroendocrine carcinoma of the liver: A rare case report
Yang, J., Li, Z., Luo, C., Du, Y., Lu, Q., Li, N., Li, H., Yu, T., & Huang, X. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1962 · Cited by 4
“Some authors recommend the use of cisplatin or carboplatin with etoposide (24), whereas others approve the combination of cisplatin with fluoropyrimidines in cases with metastatic adenopathy (25).”
Backgroundda Costa, R. D., Kemp, R., dos Santos, J. S., COSTA, D. A. P. D., Ardengh, J. C., Ribas-Filho, J. M., & Ribas, C. A. P. M. (2020) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-672020190001e1512 · Cited by 4
Cheng, J., Patel, G., Dawood, A., & Aqeel, A. (2022) · Cureus · doi:10.7759/cureus.22208 · Cited by 4
“These tumors are covered with normal mucosa; therefore, the biopsy with a deeper cut should be taken from multiple lesions, including antrum and fundus of the stomach [8].”
BackgroundA Case of Metastatic Gastric Neuroendocrine Tumor: Therapeutic Considerations
Kim, S. Y., Woo, I. S., Yang, J. H., Han, C. W., Roh, S. Y., & Jung, Y. H. (2014) · Case Reports in Oncology · doi:10.1159/000362516 · Cited by 4
Shamiyeh, A., & Gabriel, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15608 · Cited by 4
Recurrent gastric neuroendocrine tumors treated with total gastrectomy
Jung, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i46.13195 · Cited by 4
Clinicopathological features of primary gastric neuroendocrine neoplasms: A single‐center analysis
Xu, T. M., Wang, C. S., Jia, C.-W., Qian, J., & Li, J. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12326 · Cited by 4
The role of endoscopic ultrasound in the diagnosis and therapy of gastrointestinal disorders
Czakó, L., Dubravcsik, Z., Gasztonyi, B., Hamvas, J., Pakodi, F., Szepes, A., & Szepes, Z. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29866 · Cited by 3
World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC
Rogoll, D., Landwehr, L., Schreiner, J., Hartrampf, P. E., Frey, L., Hartmann, E., Meining, A. G., Gulden, S., Schnaidt, H., Chan, S. Y., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf159 · Cited by 3
68Ga-DOTATATE and 68Ga-NODAGA-JR11 PET/CT Images in a Patient With Gastric Neuroendocrine Tumor
Lin, Z., Lin, R., Zhang, J., Yao, S., & Miao, W. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003732 · Cited by 3
Lin, W., Zhu, Z., & Shang, Y. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05568-3 · Cited by 3
Serafin, M., Jabłońska, B., Senderek, E., Majewska, K., & Mrowiec, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164892 · Cited by 3
“All procedures were performed according to ENETS Guidelines [28,29].”
MethodLong‐Term Outcomes Following Endoscopic Papillectomy for Ampullary Neuroendocrine Tumors
Lee, Y., Oh, D., Hong, S., Cho, S.-H., Huh, G., Song, T. J., & Seo, D. W. (2025) · Digestive Endoscopy · doi:10.1111/den.70064 · Cited by 3
Gastrointestinal Surgery of Neuroendocrine Neoplasms
Hansen, C. P., Olsen, I. H., & Knigge, U. (2015) · Frontiers of hormone research · doi:10.1159/000382144 · Cited by 3
Self-citationBoutzios, G., Grınıatsos, J., Dimitriou, N., Zilos, A., Antoniou, S., Felekouras, E. S., & Kaltsas, G. (2013) · HORMONES · doi:10.14310/horm.2002.1439 · Cited by 3
“This is particularly relevant as treatment with long-acting somatostatin analogues (SSAs)10,11 has been shown to reduce tumor size and serum gastrin level,12 although this form of treatment is not currently recommended by the ENETS.8 In order to identify patients at higher risk for a more aggressive course of the dise…”
BackgroundMethodResultInfluentialLee, H. S., Jeon, S. W., Kim, G. H., Kim, J. I., Chung, I., Jee, S. R., Kim, H. U., Seo, G. S., Baik, G. H., Choi, K. D., et al. (2016) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2016.16.1.13 · Cited by 3
Major and Minor Duodenal Papilla Neuroendocrine Tumors in Type 1 Neurofibromatosis: Case Report
Zandomeni, M., Beltrame, M. C., de Santibañes, M., Mazza, O., Pekolj, J., de Santibáñes, E., & Clariá, R. S. (2016) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-016-9854-0 · Cited by 3
Functional and Radiological Imaging of Neuroendocrine Neoplasms
Dromain, C., Prior, J. O., & Schaefer, N. G. (2020) · Springer eBooks · doi:10.1007/978-3-030-54391-4_3 · Cited by 3
Metadata
- Authors
- Delle Fave, G., Kwekkeboom, D. J., Van Cutsem, E., Rindi, G., Kos-Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., & Ruszniewski, P.
- Affiliations
- Hôpital Louis-Mourier (FR)
- Agostino Gemelli University Polyclinic (IT)
- Copenhagen University Hospital (DK)
- Tohoku University (JP)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Hôpital Beaujon (FR)
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2012
- Volume
- 95
- Issue
- 2
- Pages
- 74-87
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2158048233
- Cited by
- 327
- References
- 138
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 14 · 2023: 27 · 2022: 25 · 2021: 22 · 2020: 22 · 2019: 17 · 2018: 18 · 2017: 22 · 2016: 36 · 2015: 45 · 2014: 27 · 2013: 19 · 2012: 9
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- neuroendocrine tumors, consensus recommendations, clinical management, gastrinoma, pancreatic neuroendocrine tumors
- MeSH terms
- Duodenal Neoplasms, Humans, Stomach Neoplasms, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.